Polyarticular juvenile idiopathic arthritis
ICD-10 M08 · ICD-11 FA24.1

Treatment of Juvenile Idiopathic Arthritis with Active Enthesitis and Contraindication to TNF Inhibitor (Age < 16)

This protocol addresses the specific clinical situation of children under 16 with juvenile idiopathic arthritis (JIA) who present with active enthesitis and have a contraindication to tumor necrosis factor inhibitor (TNFi) therapy.

Clinical Scenario

Active enthesitis refers to tenderness and/or swelling of the entheses — the sites where tendons or ligaments attach to bone — determined to require medical treatment by the treating provider. Patients in this group are most likely from ILAR categories of enthesitis-related arthritis, psoriatic arthritis, and undifferentiated arthritis, though any JIA category may be represented.

The presence of a contraindication to TNFi therapy defines this as a distinct management situation, requiring a specific approach to first-line anti-inflammatory treatment.

Treatment Approach

First-line management for this group centres on NSAID-based anti-inflammatory treatment. The complete structured protocol — covering the recommended agent class, sequencing considerations specific to patients with TNFi contraindications, and further therapeutic options — is available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1002/acr.23870

In children and adolescents with JIA and active enthesitis, NSAID treatment is strongly recommended over no treatment with an NSAID.

This group is intended to include patients with enthesitis (inflammation at tendon-to-bone insertion sites) who will also most likely be from the ILAR categories of enthesitis-related arthritis, psoriatic arthritis, and undifferentiated arthritis but may include patients from any of the ILAR JIA categories.

For the purposes of this guideline, active enthesitis is tenderness and/or swelling of the entheses determined to require medical treatment per the treating provider.

The Voting Panel discussed that a trial of methotrexate or sulfasalazine may be warranted for patients with contraindications to TNFi, patients with mild enthesitis, and patients with concomitant active peripheral polyarthritis.

View source ↗